Revolution Medicines (RVMD) Accumulated Depreciation & Amortization (2018 - 2026)

Revolution Medicines has reported Accumulated Depreciation & Amortization for 9 years, with the latest figure at $30.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Depreciation & Amortization rose 31.22% year-over-year to $30.7 million; the trailing twelve-month figure through Mar 2026 stood at $30.7 million (up 31.22% YoY), and the FY2025 full-year result was $28.5 million, up 30.66% from the prior year.
• Accumulated Depreciation & Amortization for Q1 2026 stood at $30.7 million, up from $28.5 million in the prior quarter.
• The five-year high for Accumulated Depreciation & Amortization was $30.7 million in Q1 2026, with the low at $900000.0 in Q1 2022.
• Average Accumulated Depreciation & Amortization over 5 years is $16.5 million, with a median of $18.9 million recorded in 2024.
• Year-over-year, Accumulated Depreciation & Amortization sank 56.52% in 2022 and jumped 1769.89% in 2023.
• Tracing RVMD's Accumulated Depreciation & Amortization over 5 years: stood at $4.0 million in 2022, then increased by 25.0% to $5.0 million in 2023, then soared by 336.46% to $21.8 million in 2024, then jumped by 30.66% to $28.5 million in 2025, then climbed by 7.6% to $30.7 million in 2026.
• The last three Accumulated Depreciation & Amortization figures came in at $30.7 million (Q1 2026), $28.5 million (Q4 2025), and $27.0 million (Q3 2025), per Business Quant data.

Peer Comparison